Recruitment

Recruitment Status
Completed

Inclusion Criteria

Index event of non-ST or ST segment elevation ACS
Age 18 and more
Provision of signed informed consent
Index event of non-ST or ST segment elevation ACS
Age 18 and more
Provision of signed informed consent

Exclusion Criteria

Any other reason the investigator deems the subject to be unsuitable for the study e.g., Active malignant tumor
Oral anticoagulation therapy that cannot be stopped
History of cerebral hemorrhage, gastrointestinal bleeding within 6months, major surgical procedure within 30days
...
Any other reason the investigator deems the subject to be unsuitable for the study e.g., Active malignant tumor
Oral anticoagulation therapy that cannot be stopped
History of cerebral hemorrhage, gastrointestinal bleeding within 6months, major surgical procedure within 30days
Mental condition (dementia, alcohol or drug abuse) which may be affect study compliance or prevent understanding of the aims, investigational procedures or possible consequences of the study
Treated with thrombolysis within 24hrs
Subjects requiring dialysis
Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic index, or strong CYP3A inducers
Hypersensitivity to aspirin or ticagrelor
The conditions associated with increased risk of bradycardiac events
Positive pregnancy test or is known to be pregnant
Thrombocytopenia or leukopenia
Any life-threatening condition with life expectancy less than 6months
Subjects with severe liver disease
Increased bleeding risk
High risk due to malignant hypertension

Summary

Conditions
  • Acute Coronary Syndrome
  • Angina Pectoris
  • Cardiovascular Diseases
  • Heart Diseases
  • Myocardial Ischemia
Type
Interventional
Phase
Phase 4
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criteria

Index event of non-ST or ST segment elevation ACS
Age 18 and more
Provision of signed informed consent
Index event of non-ST or ST segment elevation ACS
Age 18 and more
Provision of signed informed consent

Exclusion Criteria

Any other reason the investigator deems the subject to be unsuitable for the study e.g., Active malignant tumor
Oral anticoagulation therapy that cannot be stopped
History of cerebral hemorrhage, gastrointestinal bleeding within 6months, major surgical procedure within 30days
...
Any other reason the investigator deems the subject to be unsuitable for the study e.g., Active malignant tumor
Oral anticoagulation therapy that cannot be stopped
History of cerebral hemorrhage, gastrointestinal bleeding within 6months, major surgical procedure within 30days
Mental condition (dementia, alcohol or drug abuse) which may be affect study compliance or prevent understanding of the aims, investigational procedures or possible consequences of the study
Treated with thrombolysis within 24hrs
Subjects requiring dialysis
Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic index, or strong CYP3A inducers
Hypersensitivity to aspirin or ticagrelor
The conditions associated with increased risk of bradycardiac events
Positive pregnancy test or is known to be pregnant
Thrombocytopenia or leukopenia
Any life-threatening condition with life expectancy less than 6months
Subjects with severe liver disease
Increased bleeding risk
High risk due to malignant hypertension

Locations

Gyeongju
Dae-jeon
Seoul, Songpa-gu, 138-736
Daegu
Ilsan
...
Gyeongju
Dae-jeon
Seoul, Songpa-gu, 138-736
Daegu
Ilsan
Incheon
Ulsan
Pusan
Pusan
Jeonju

Tracking Information

NCT #
NCT02094963
Collaborators
CardioVascular Research Foundation, Korea
Investigators
Not Provided